STMN-1 gene: A predictor of survival in stage IIA esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy?

Annals of Surgical Oncology

Volumn 21, Issue 1, 2014, Pages 315-321

  Akhtar, Javed ^a   Wang, Zhou ^a   Yu, Che ^a   Zhang, Zhi Ping ^a   Bi, Ming Ming ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; PARAFFIN; PHOSPHOPROTEIN; STMN 1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IVOR LEWIS ESOPHAGECTOMY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SURVIVAL RATE;

CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATHMIN; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84891745153     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3215-z     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008.GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.
3. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137-50.
4. Stahl M, Budach W, Meyer HJ, Cervantes A, ESMO Guidelines Working Group. Esophageal cancer: clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v46-9.
5. Song Y, Wang Z, Liu X, Jiang W, Shi M. CCR7 and VEGF-C: molecular indicator of lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy? Ann Surg Oncol. 2012;19(11):3606-12.
6. Chen G, Wang Z, Liu XY, Liu FY. Adjuvant radiotherapy after modified Ivor-Lewis esophagectomy: can it prevent lymph node recurrence of the mid-thoracic esophageal carcinoma? Ann Thorac Surg. 2009;87(6):1697-702.
7. Sobel A. Stathmin: a relay phosphoprotein for multiple signal transduction. Trends Biochem Sci. 1991;16(8):301-5.
8. Sherbet GV, Cajone F. Stathmin in cell proliferation and cancer progression. Cancer Gen Proteom. 2005;2(4):227-37.
9. Rana S, Maples PB, Senzer N, Nemunaitis J. Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther. 2008;8(9):1461-70.
10. Rana S, Maples PB, Senzer N, Nemunaitis J. Expression of stathmin in esophageal squamous cell carcinoma and its biological significance. Nan Fang Yi Ke Da Xue Xue Bao. 2010;30(7):1552-7.
11. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th edn. Oxford: Wiley-Blackwell; 2009.
12. Chen G, Wang Z, Liu XY, Zhang MY, Liu FY. Clinical study of modified Ivor-Lewis esophagectomy plus adjuvant radiotherapy for local control of stage IIA squamous cell carcinoma in the mid-thoracic esophagus. Eur J Cardiothorac Surg. 2009;35(1):1-7.
13. Wang Z, Liu XY, Liu FY, Chen JH. A study of correlation between early postoperative relapse with lymph node micrometastasis in patients with N0 esophageal cancer. Zhonghua Wai Ke Za Zhi. 2004;42(2):68-71.
14. Olsen JR, Dehdashti F, Siegel BA, Zighelboim I, Grigsby PW, Schwarz JK. Prognostic utility of squamous cell carcinoma antigen in carcinoma of the cervix: association with pre- and posttreatment FDG-PET. Int J Radiat Oncol Biol Phys. 2011;18(3):772-7.
15. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347(21):1662-9.
16. Goldminc M, Maddern G, Le Prise E, Meunier B, Campion JP, Launois B. Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial. Br J Surg. 1993;80(3):367-70.
17. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51(1):15-36.
18. Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg. 2004;198(2):205-11.
19. Shimada H, Kitabayashi H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, et al. Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery. 2003;133(1):24-31.
20. Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter WL, Liao Z, et al. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer. 2006;106(5):1017-25.
21. Natsugoe S, Yoshinaka H, Shimada M, Sakamoto F, Morinaga T, Nakano S, et al. Number of lymph node metastases determined by presurgical ultrasound and endoscopic ultrasound is related to prognosis in patients with esophageal carcinoma. Ann Surg. 2001;234(5):613-8.
22. Baba M, Aikou T, Natsugoe S, Kusano C, Shimada M, Nakano S, et al. Quality of life following esophagectomy with three-field lymphadenectomy for carcinoma, focusing on its relationship to vocal cord palsy. Dis Esophagus. 1998;11(1):28-34.
23. Matsubara T, Ueda M, Takahashi T, Nakajima T, Nishi M. Localization of recurrent disease after extended lymph node dissection for carcinoma of the thoracic esophagus. J Am Coll Surg. 1996;182(4):340-6.
24. Tachibana M, Kinugasa S, Yoshimura H, Shibakita M, Tonomoto Y, Dhar DK, et al. Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma. Am J Surg. 2005;189(1):98-109.
25. Fujita H, Sueyoshi S, Tanaka T. Three-field dissection for squamous cell carcinoma in the thoracic esophagus. Ann Thorac Cardiovasc Surg. 2002;8(6):328-35.
26. Chen G, Wang Z, Liu XY, Liu FY. Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esophagectomy. World J Surg. 2007;31(5):1107-14.
27. Kuo MF, Wang HS, Kuo QT, Shun CT, Hsu HC, Yang SH, et al. High expression of stathmin protein predicts a fulminant course in medulloblastoma. J Neurosurg Pediatr. 2009;4(1):74-80.
28. Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, Higo M, et al. Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer. 2006;94:717-23.
29. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA. 2007;104(18):7564-9.
30. Golouh R, Cufer T, Sadikov A, Nussdorfer P, Usher PA, Brünner N, et al. The prognostic value of stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. Breast Cancer Res Treat. 2008;110(2):317-26.
31. Brattsand G. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer 2000;83(3):311-8.
32. Lin WC, Chen SC, Hu FC, Chueh SC, Pu YS, Yu HJ, et al. Expression of stathmin in localized upper urinary tract urothelial carcinoma: correlations with prognosis. Urology. 2009;74(6):1264-9.
33. Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, Menato G, et al. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer. 2009;115(11):2453-63.
34. Xi W, Rui W, Fang L, Ke D, Ping G, Hui-Zhong Z. Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients. J Cancer Res Clin Oncol. 2009;135(6):837-46.
35. Liu F, Sun YL, Xu Y. Expression and phosphorylation of stathmin correlate with cell migration in esophageal squamous cell carcinoma. Oncol Rep. 2013;29(2):419-24.